pills (white). There should have been only one row of placebos. It wasn't until Mar. 28, the Thursday before the Easter long weekend, that the company decided to recall the affected lot. The notice of recall, however, wasn't sent to wholesalers, distributors and retailers until the following Wednesday (Apr. 3).
Apotex assessed the risk level for the recall as type II, meaning that users might experience temporary adverse health consequences.
On Friday, Apr. 5, Health Canada reassessed the risk. It determined it was still type II for the general population but type I (reasonable chance of death or serious health problems) for "vulnerable populations." These were identified as women who should not get pregnant for medical reasons or were using contraindicated therapy. But the department waited until after the weekend to release a public communication about the recall.
The media and the public, however, heard the news before Monday. The drugstore chain London Drugs posted the recall notice on its blog on Saturday, Apr. 6. The blog post "was not anticipated and is not standard, but it shone a spotlight on the absence of Health Canada notification," states the review.
Over the weekend, media picked up the story based on the available information, which was limited and unclear. The review cites this as evidence that "traditional models of communications no longer apply." In the 24-7, Internet era, Health Canada should develop "greater agility in preparing and providing information."
Health Canada received heavy criticism, mainly for not doing its job as a pharmaceutical regulator, but also for not recognizing the psychosocial importance of an unplanned pregnancy. The review recommends that Health Canada employees involved with drug recalls receive training about "social sensitivities" of some drugs, including contraceptives, and about risks unrelated to physical health.
The review also notes, however, that Health Canada has no legal power to order recalls and little means to compel drug companies to more quickly notify it of recalls. The public response to the Alysena 28 recall suggests that Canadians have high expectations for Health Canada as a drug regulator "that are not achievable with the present legislative and regulatory provisions," states the review.
Health Canada publishes information about drug recalls, monitors drug recalls as they occur and can request drug recalls, but does not conduct recalls. The US Food and Drug Administration serves a similar role, but also has legal authority to order a drug recall. -Catherine Cross, CMAJ
